Company
Bio Rad Laboratories
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
15
510(k), De Novo and PMA
Device trials
2
As lead sponsor, any status
Adverse event reports
1
Received Nov 1, 2025 to Nov 20, 2026
Recall records
92
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements.
Listed
BIO
NYSE · BIO-RAD LABORATORIES, INC.
Public float
Unknown
Not reported in US filings
Revenue
$2.58B
Fiscal year ending Dec 31, 2025
Net income
$760M
Fiscal year ending Dec 31, 2025
R&D spending
$276M
Fiscal year ending Dec 31, 2025
Cash
$465M
As of Sep 30, 2026
Long-term debt
$1.20B
As of Sep 30, 2026
Shares outstanding
Not reported
Capital raised as a public company
Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.
| Year | IPO | Stock sold | Long-term debt | Convertible debt |
|---|---|---|---|---|
| 2022 | – | $3.4M | – | – |
| 2021 | – | -$1.9M | – | – |
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
The investor database is free with an account
Sign up free with your name, company and ZIP code to see the 5%+ shareholders and government grant funders behind device companies.
Latest FDA decisions
The 8 newest of 15 since 2015.
- BioPlex 2200 Lyme Total510(k)
K183446 · Decided Mar 12, 2019 · 90 days after receipt
Device type: Reagent, Borrelia Serological Reagent (LSR) · Laboratory Medicine & Pathology
14 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
NCT02401555 · 419 participants · Start Apr 2013 · Primary completion Dec 2013
Device: Geenius HIV1/2 Supplemental Assay · For: HIV
Sites: San Francisco, California; Atlanta, Georgia; Silver Spring, Maryland · 5 sites in all
1 more trials with a free account
Reports received
1
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
0.0% of reports
Injury reports
1
100% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 10 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 1 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 1 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2515-2025 · Started May 30, 2025 · Posted by FDA Sep 4, 2025
Reason given: Due to a risk of false positive results that could lead to unnecessary medical treatment.
Cause as FDA categorized it: Process control · Device type: Enzyme Linked Immunoabsorbent Assay, Toxoplasma Gondii (LGD)
91 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.